JGC
TSHA icon

J. Goldman & Co’s Taysha Gene Therapies TSHA Stock Holding History

J. Goldman & Co’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Buy
67,349
+33,599
+100% +$199K 0.01% 563
2026
Q1 		$151K Hold
33,750
– – ﹤0.01% 610
2025
Q4 		$186K Buy
+33,750
New +$164K ﹤0.01% 515

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

J. Goldman & Co's TSHA Position: Q2 2026 in Review

J. Goldman & Co increased its Taysha Gene Therapies (TSHA) stake by 100% in Q2 2026, buying an estimated $199K and bringing the position to 67,349 shares worth $459K. The position accounts for 0.01% of the portfolio, ranked #563.

J. Goldman & Co first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • J. Goldman & Co held 67,349 shares of Taysha Gene Therapies worth $459K as of Q2 2026.
  • J. Goldman & Co bought 33,599 Taysha Gene Therapies shares in Q2 2026, an estimated $199K.
  • Taysha Gene Therapies made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #563 holding.
  • J. Goldman & Co first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.